DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer

Information source: Tata Memorial Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Operable Breast Cancer

Intervention: 0.5% lignocaine 60mM (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Tata Memorial Hospital

Official(s) and/or principal investigator(s):
Rajendra A Badwe, MS, Principal Investigator, Affiliation: Director and professor, Surgical Oncology

Overall contact:
Rohini Hawaldar, BSc DCM, Phone: 91-22-2416 8601, Email: rwhawaldar@gmail.com

Summary

Voltage Gated Sodium Channels Over the years, there is more evidence that ionic channels are involved in the oncogenic process. Among these, voltage gated sodium channels (VGSC) expressed in non-nervous or non-muscular organs are often associated with the metastatic behavior of different cancers. Expression of VGSCs has been reported both in vitro and/or in vivo in a range of human carcinomas, including breast cancer Ion channels are major signaling molecules expressed in a wide variety of tissues. They are involved in determining a variety of cellular functions like proliferation, solute transport, volume control, enzyme activity, secretion, invasion, gene-expression, excitation-contraction coupling, and intercellular communication. 4 VGSC activity contributes to much cellular behavior integral to metastasis, including cellular process extension, lateral motility and galvanotaxis, transverse invasion, and secretory membrane activity. A correlation between Na transport and oncogenesis has been widely reported in literature. In 1980, transformed mouse mammary cells were shown to have 3-fold higher intra-cellular sodium content than untransformed cells. 5 Additionally evidence suggest that increasing the inward sodium current through voltage gated sodium channels increased the invasive capacity of breast cancer. 6 Also, growth and proliferation of mammary adenocarcinoma cells can be inhibited by Amiloride suggesting that epithelial Na channels (ENaC) activity is correlated with proliferation of breast cancer cells Current evidence suggests that VGSC activity is necessary and sufficient for cancer cell invasiveness8. A recent in vitro study has shown that the human MDA MB 231 breast cancer cell line expressed functional VGSCs9. However, the molecular nature of the VGSC and its functional relevance to breast cancer in vivo are currently under study. Surgical operations for cancer have been reported to induce dissemination of cancer cells into surrounding tissues or into the circulation10,11and infiltration anesthetics can inhibit immune response12-14. Although the mechanism remains to be elucidated, infiltration anesthetics such as lidocaine have membrane- stabilizing action (Seeman, 1972) and these agents could have direct effects on cancer cells. Therefore, it is important to clarify the effects of infiltration anesthetics on behavior of the tumor cells. Commonly used local anesthetic agents inhibit the VGSCs and also possess a unique membrane stabilizing action through other unknown mechanisms. A study by Mammota et al 15 reported that lignocaine, effectively inhibited the invasive ability of human cancer (HT1080, HOS, and RPMI-7951) cells at concentrations used in surgical operations (5-20 mM). Lidocaine reduced the invasion ability of these cells by partly inhibiting the shedding of HB-EGF from the cell surface and modulation of intracellular Ca2+ concentration contributed to this action. In addition, lidocaine (5-30 mM) infiltrated around the inoculation site, inhibited pulmonary metastases of murine osteosarcoma (LM 8) cells in vivo. Dose of lidocaine15: 40 mM (1%) lidocaine is usually used for infiltration anesthesia for surgical operations. Lower concentrations (1-20mM) of lidocaine were sufficient to suppress the invasive ability of cancer cells14. One mM lidocaine inhibited the invasive ability of HT1080 cells by about 50%, and 20 mM lidocaine inhibited the invasion ability completely. Lidocaine also inhibited dose-dependently the invasive ability of HOS and RPMI-7951 cells, although it was less effective on HOS cells. Lignocaine exerts its anesthetic action by obstructing the sodium channel 16 however, 10 mMof tetrodotoxin (TTX), a specific sodium channel inhibitor, had little effect on the invasive ability of HT1080 cells. Ten mM lidocaine-N-ethylbromide (NEB), which does not cross the cell membrane, also had little effect on the invasive ability of the cells. Objectives Primary Objective: • To assess the in-vivo ability of local anesthetics agents like lignocaine to decrease the dissemination of cancer cells during surgery and improve the disease free interval Secondary Objective • To assess the in-vivo ability of local anesthetics agents like lignocaine on impacting long term survival. Methodology / Treatment plan The study drug (0. 5% lidocaine 60mM) will be tested in the intraoperative setting prior to surgery will be tested in a randomized setting.: Arm A: 60mM of 0. 5% lignocaine will be injected peritumoral prior to excision. The local anesthetic should be injected on all 6 surfaces of the tumor and also within the tumor. Wait for 7 minutes for its action followed by surgery. (Intervention arm) Arm B: No injection of lignocaine prior to excision (Control arm)

Clinical Details

Official title: Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: • To assess the in-vivo ability of local anesthetics agents like lignocaine to decrease the dissemination of cancer cells during surgery and improve the disease free interval

Secondary outcome: • To assess the in-vivo ability of local anesthetics agents like lignocaine on impacting long term survival

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Female.

Criteria:

Inclusion Criteria: 1. All women with operable breast cancer planned for upfront surgery 2. Histologically proven or clinically suspicious breast cancer Exclusion Criteria: 1. Previous history of lumpectomy or incision biopsy 2. Distant metastases 3. Neoadjuvant Chemotherapy 4. History of allergy to drugs (lignocaine) 5. High risk factors precluding the use of lignocaine 6. Previous history of cancer

Locations and Contacts

Rohini Hawaldar, BSc DCM, Phone: 91-22-2416 8601, Email: rwhawaldar@gmail.com

Kolhapur Cancer Centre PVT LTD, Kolhapur, Maharashtra 416008, India; Recruiting
Suraj B Pawar, MS. FICS, Phone: 91-231-2532034, Email: surajpawar2001@yahoo.co.in
Suraj B Pawar, MS.FICS, Principal Investigator

Tata Memorial Centre Mumbai, Mumbai, Maharashtra 400012, India; Recruiting
Rajendra A Badwe, MS, Phone: 91-022-24177000, Ext: 4265, Email: badwera@gmail.com
Rajendra A Badwe, MS, Principal Investigator

Shree Siddhivinayak Ganapti Cancer Hospital Sangli, Sangli, Maharashtra 416410, India; Recruiting
Priyadarshan V Chitale, MS, Phone: 91-9850057556, Email: priyadarshanchitle@hotmail.com
Priyadarshan V Chitale, Principal Investigator

Additional Information

Starting date: December 2011
Last updated: June 10, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017